{"filing":{"accession_number":"0001703057-26-000044","cik":"0001703057","ticker":"ABCL","company_name":"AbCellera Biologics Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"abcl-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000044/abcl-20260805.htm"},"events":[{"id":25218,"run_id":22882,"accession_number":"0001703057-26-000044","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"AbCellera issued a press release on August 5, 2026 announcing Q2 2026 financial results, including revenue of $4.1 million, net loss of $55.4 million, and cash balances of over $565 million, along with business updates on clinical programs and new collaborations with Jazz and Vertex.","company_name":"AbCellera Biologics Inc.","ticker":"ABCL","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25984,"accession_number":"0001703057-26-000044","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"AbCellera issued a press release on August 5, 2026 announcing financial and operational results for Q2 2026 (quarter ended June 30, 2026), including revenue of $4.1 million, R\u0026D expenses of $46.0 million, net loss of $55.4 million, and cash balances of over $565 million. The disclosure includes condensed consolidated financial statements (income statement, balance sheet, and cash flow statement) and is a standard quarterly earnings announcement material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:20:07.854155+00:00","company_name":"","ticker":null,"filing_date":""},{"id":25985,"accession_number":"0001703057-26-000044","item_number":"7.01","item_title":"Regulation FD","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references an earnings call on August 5, 2026, to discuss Q2 2026 results, with a corporate presentation furnished as Exhibit 99.2. The attached exhibits include a detailed earnings press release (EX-99.1) disclosing Q2 2026 financial results—revenue of $4.1 million, net loss of $55.4 million, and cash balances of $565 million—along with business updates on clinical programs and new collaborations with Jazz and Vertex. This is a standard quarterly earnings release disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:20:07.854155+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25984,"accession_number":"0001703057-26-000044","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"AbCellera issued a press release on August 5, 2026 announcing financial and operational results for Q2 2026 (quarter ended June 30, 2026), including revenue of $4.1 million, R\u0026D expenses of $46.0 million, net loss of $55.4 million, and cash balances of over $565 million. The disclosure includes condensed consolidated financial statements (income statement, balance sheet, and cash flow statement) and is a standard quarterly earnings announcement material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:20:07.854155+00:00","company_name":"AbCellera Biologics Inc.","ticker":"ABCL","filing_date":"2026-08-05"},{"id":25985,"accession_number":"0001703057-26-000044","item_number":"7.01","item_title":"Regulation FD","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references an earnings call on August 5, 2026, to discuss Q2 2026 results, with a corporate presentation furnished as Exhibit 99.2. The attached exhibits include a detailed earnings press release (EX-99.1) disclosing Q2 2026 financial results—revenue of $4.1 million, net loss of $55.4 million, and cash balances of $565 million—along with business updates on clinical programs and new collaborations with Jazz and Vertex. This is a standard quarterly earnings release disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:20:07.854155+00:00","company_name":"AbCellera Biologics Inc.","ticker":"ABCL","filing_date":"2026-08-05"}]}